LPTX
Leap Therapeutics, Inc.NASDAQHealthcare$0.77-3.15%ClosedMarket Cap: $31.9M
As of 2026-04-06
Valuation
P/E (TTM)
6.61
PEG
0.06
P/B
0.33
P/S
208.80
EV/EBITDA
-0.73
DCF Value
$2.17
FCF Yield
-207.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
-9631.6%
Operating Margin
-19649.3%
Net Margin
-8537.8%
ROE
-16.9%
ROA
-10.9%
ROIC
-12.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-5.1M | $62.9M | $0.92 | — |
| FY 2025 | $0.00 | NaN% | $-36.5M | $4.8M | $0.07 | — |
| Q3 2025 | $209.0K | -9631.6% | $-3.2M | $-26.0M | $-0.08 | — |
| Q2 2025 | $0.00 | NaN% | $-16.9M | $-16.6M | $-0.40 | — |
| Q1 2025 | $0.00 | NaN% | $-15.9M | $-15.4M | $-0.37 | — |
| Q4 2024 | $234.0K | -4461.5% | $-45.0M | $-40.2M | $-0.37 | — |
| FY 2024 | $0.00 | NaN% | $-70.1M | $-67.6M | $-1.81 | — |
| Q3 2024 | $0.00 | NaN% | $-17.9M | $-18.2M | $-0.44 | — |
| Q2 2024 | $0.00 | NaN% | $-21.3M | $-20.1M | $-0.51 | — |
| Q1 2024 | $0.00 | NaN% | $-14.8M | $-13.8M | $-0.51 | — |
| Q4 2023 | $337.0K | -1713.6% | $-11.7M | $-24.7M | $-0.46 | — |
| FY 2023 | $0.00 | -Infinity% | $-87.0M | $-81.4M | $-3.98 | — |